Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (DE:DUL)
FRANKFURT:DUL
Holding DE:DUL?
Track your performance easily
DUL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€132.70 - €276.90
Previous Close€258.6
Volume0.00
Average Volume (3M)65.00
Market Cap
€32.64B
Enterprise Value€31.26B
Total Cash (Recent Filing)$2.78B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Feb 06, 2025EPS Estimate
-€0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,980,917
10 Day Avg. Volume12
30 Day Avg. Volume65
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1002.80
Price to Sales (P/S)16.56
Price to Cash Flow (P/CF)198.40
P/FCF Ratio219.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.92
Enterprise Value/Gross Profit20.59
Enterprise Value/Ebitda-169.44
Forecast
1Y Price Target
€289.59Price Target Upside11.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering24
Alnylam Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsUpdated Phase 1 data for ALN-TTRsc04 will be presented at the American Heart Association Scientific Sessions, with Phase 3 development plans being a major catalyst for shares long-term.
Market PotentialThe launch of AMVUTTRA in ATTR-CM is on track for blockbuster potential with over $5 billion in annual revenue.
Product ExpansionAlnylam is set to expand its approved Amvuttra into the much larger cardiomyopathy indication, positioning it as a primary driver of the stock.
Bears Say
Financial PerformanceOnpattro sales were $50M, missing consensus by 22%, indicating a decrease in QoQ sales.
Market AccessAmvuttra is either not covered or 'effectively' not covered in several Medicare segments, disadvantaged in MAPD & non-Medicare, and advantaged in Medigap-related segments.
Product DevelopmentFurther development of ALN-KHK, an SC-dosed RNAi therapeutic targeting ketohexokinase for the treatment of type 2 diabetes, has been suspended.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.37% Insiders
48.38% Mutual Funds
31.12% Other Institutional Investors
4.82% Public Companies and
Individual Investors
DUL FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was €132.70 and its highest was €276.90 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Feb 06, 2025 which is in 84 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Oct 31, 2024. The company reported -€0.817 earnings per share for the quarter, beating the consensus estimate of -€0.861 by €0.044.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -€0.55.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 128,980,910 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -€0.817 in its last earnings report, beating expectations of -€0.861. Following the earnings report the stock price went down -1.801%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 919M.
---
Alnylam Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€289.59 (11.98% Upside)
€289.59 (11.98% Upside)
Blogger Sentiment
Bullish
DE:DUL Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.53%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
DUL Company Deck
---
DUL Earnings Call
Q3 2024
0:00 / 0:00
---
DUL Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
DUL Stock 12 Month Forecast
Average Price Target
€289.59
▲(11.98% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Arrowhead Pharmaceuticals
―
Moderna
―
BioMarin Pharmaceutical
―
Best Analysts Covering DUL
1 Year
1 Year Success Rate
18/22 ratings generated profit
1 Year Average Return
+23.15%
reiterated a buy rating 2 months ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +23.15% per trade.
---